RIDGEFIELD, Conn. and
INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- The Duke
Clinical Research Institute (DCRI) is leading a new clinical study
to optimize care for people with type 2 diabetes and cardiovascular
disease through evaluation of a multidisciplinary approach at
cardiology clinics across the U.S. The research program,
COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized
Trial of Interventions to Improve OutcomEs), will be funded by
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).
"The public health impact of type 2 diabetes and cardiovascular
disease in the U.S. is immense," said Christopher Granger, M.D., professor of medicine
in the Division of Cardiology at Duke
University and lead researcher for COORDINATE-Diabetes.
"While highly effective evidence-based treatments have been
developed, these treatments are not consistently used, and thus
preventable death and disability are occurring. Our goal with
COORDINATE-Diabetes is to better understand the effectiveness of
specific interventions at cardiology clinics to achieve best
practices for improving patient health."
People with diabetes are up to four times more likely to develop
cardiovascular disease than those without diabetes, and
cardiovascular disease ranks as their leading cause of death and
disability despite available treatments. To help improve these
striking statistics, COORDINATE-Diabetes will examine the impact of
multifaceted interventions involving guideline-based therapies
among cardiologists, endocrinologists, primary care
providers and patients, including the recommendations outlined
in the American Diabetes Association (ADA) 2018 Standards of
Medical Care in Diabetes and the American College of Cardiology
(ACC) Expert Consensus Decision Pathway on novel therapies for
cardiovascular risk reduction in adults with type 2 diabetes and
atherosclerotic cardiovascular disease.
The trial will include 46 cardiology clinics in the U.S. and
aims to enroll 30 patients at each site. The clinics will be
randomized to a basic education arm (in which patients will be
treated by clinicians who receive only basic information about
guideline-based therapy) or an intensive intervention arm (that
focuses on coordinating care between cardiologists and
endocrinologists to develop and implement an integrated,
multidisciplinary care pathway). The care teams at the intervention
sites will be encouraged to communicate with patients' primary care
physicians to facilitate a well-rounded, multidisciplinary approach
to patient care. The trial will measure the impact of the
intervention on the sites' use of guideline-recommended therapies
after 12 months.
"We are pleased to support evidence-based research to understand
how to best manage risks and optimize care for patients with type 2
diabetes and cardiovascular disease in a real-world, clinical
setting," said Thomas Seck, M.D., senior vice president, Medicine
and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
"Although there are treatments with proven cardiovascular benefits
recommended by the ADA and other organizations, many healthcare
providers are not prescribing them to all their patients who may
benefit. We look forward to learning more about how healthcare
providers can work together to improve adherence to these treatment
guidelines in the quest to reduce patients' cardiovascular
risk."
The trial will also leverage the power of electronic health
record data from a consortium of health systems across the U.S.
that have curated their data to support research and improve
outcomes. Researchers will begin enrolling clinics and patients for
the study in 2019 with the goal of sharing the main results by
2021.
"Few rigorous studies have tested the effectiveness of a
multidisciplinary approach to improving care among this
vulnerable patient population," noted Sherry Martin, M.D., vice president, Medical
Affairs, Lilly. "Given the serious cardiovascular complications
associated with type 2 diabetes, it is important for cardiologists
and endocrinologists to work collaboratively to help improve care
for people with type 2 diabetes and cardiovascular disease."
About Diabetes and Cardiovascular
Disease
Approximately 30 million Americans and an estimated
425 million people worldwide have diabetes, and nearly 24 percent
of Americans with diabetes—or more than 7 million people—are
undiagnosed. In the U.S., approximately 12 percent of those aged 18
and older have diabetes. Type 2 diabetes is the most common
type, accounting for an estimated 90 to 95 percent of all diagnosed
adult diabetes cases in the U.S. Diabetes is a chronic condition
that occurs when the body does not properly produce or use the
hormone insulin.
Due to the complications associated with diabetes, such as high
blood sugar, high blood pressure and obesity, cardiovascular
disease is a major complication and the leading cause of death
associated with diabetes. People with diabetes are up to four times
more likely to develop cardiovascular disease than people without
diabetes. Approximately 50 percent of deaths in people with type 2
diabetes worldwide and approximately two-thirds of deaths in people
with type 2 diabetes in the U.S. are caused by cardiovascular
disease. In the U.S., healthcare costs for managing cardiovascular
conditions in patients with diabetes totaled more than $23 billion in 2012.
Having a history of diabetes at age 60 can shorten a person's
lifespan by as much as six years compared with someone without
diabetes. And having both diabetes and a history of heart attack or
stroke at age 60 can shorten a person's lifespan by as much as 12
years compared with someone without these conditions.
Boehringer Ingelheim and Eli Lilly and Company
In
January 2011, Boehringer Ingelheim
and Eli Lilly and Company announced an alliance in diabetes that
centers on compounds representing several of the largest diabetes
treatment classes. This alliance leverages the strengths of two of
the world's leading pharmaceutical companies. By joining forces,
the companies demonstrate commitment in the care of patients with
diabetes and stand together to focus on patient needs. Find out
more about the alliance at www.boehringer-ingelheim.com or
www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S.
subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical
companies. Headquartered in Ingelheim, Germany, the company operates globally with
approximately 50,000 employees. Since its founding in 1885, the
company has remained family-owned and today creates value through
innovation for three business areas including human
pharmaceuticals, animal health and biopharmaceutical contract
manufacturing.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and their
families. Our employees create and engage in programs that
strengthen our communities. Please visit
www.boehringer-ingelheim.us/csr to learn more about how we make
more health through our Corporate Social Responsibility
initiatives.
In 2017, Boehringer Ingelheim achieved net sales of about
$20.4 billion (18.1 billion euros). R&D expenditure
corresponds to approximately $3.4
billion (three billion euros),
or 17.0 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us,
or follow us on Twitter @BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we
introduced the world's first commercial insulin. Today we are
building upon this heritage by working to meet the diverse needs of
people with diabetes and those who care for them. Through research
and collaboration, a wide range of therapies and a continued
determination to provide real solutions—from medicines to support
programs and more—we strive to make life better for all those
affected by diabetes around the world. For more information, visit
www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us
at www.lilly.com and
newsroom.lilly.com/social-channels.
P-LLY
MPR-US-100698
CONTACT:
Jennifer
Forsyth
Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: jennifer.forsyth@boehringer-ingelheim.com
Phone: (203) 791-5889
Greg Kueterman
Director of Communications
Lilly Diabetes and Lilly USA
Email: kueterman_gregory_andrew@lilly.com
Phone: (317) 277-4021
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-partner-with-duke-clinical-research-institute-to-advance-multidisciplinary-care-for-people-with-type-2-diabetes-and-cardiovascular-disease-300764687.html
SOURCE Eli Lilly and Company